<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00487799</url>
  </required_header>
  <id_info>
    <org_study_id>Ularitide-1503</org_study_id>
    <nct_id>NCT00487799</nct_id>
  </id_info>
  <brief_title>A Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Ularitide in the Treatment of Subjects With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Facet Biotech</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Facet Biotech</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) of ularitide in the treatment of subjects&#xD;
      hospitalized with symptomatic acute decompensated heart failure (ADHF).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Facet no longer has ownership of ularitide.&#xD;
  </why_stopped>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The MTD of ularitide infused over 48 hours.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency, severity, and relationship of AEs and serious adverse events (SAEs) to study drug through Day 32 (ie, 30 days following the end of study drug infusion).</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical examinations, vital signs, electrocardiography, and clinical laboratory values through 48 hours.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decline in renal function defined as a &gt;25% rise or a 0.3 mg/dL increase in serum creatinine from pre-dose at baseline to 48 hours post the end of infusion and through Day 32.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile including Css, AUC, CL, V, and t½ up to 2 hours post end of infusion.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ularitide-specific anti-drug antibodies (ADAb) through Day 32.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">32</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ularitide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        To be considered eligible for inclusion, subjects must meet all of the following criteria:&#xD;
&#xD;
          -  Males and females who are 18 years or older.&#xD;
&#xD;
          -  Unplanned hospitalization for ADHF.&#xD;
&#xD;
          -  Randomization should occur as soon as possible from presentation to emergency&#xD;
             department or hospital for ADHF up to 24 hours from admission.&#xD;
&#xD;
          -  Dyspnea at rest as assessed by the subject not more than 1 hour prior to&#xD;
             randomization. Subjects must have the ability to interpret and report self-assessed&#xD;
             dyspnea.&#xD;
&#xD;
          -  At least 1 of the following 2 criteria:&#xD;
&#xD;
               1. Prior medical history of CHF (eg, prior hospitalization for CHF or left&#xD;
                  ventricular ejection fraction &lt;40%, as determined by transthoracic&#xD;
                  echocardiography at the time of screening or previously determined and documented&#xD;
                  in the patient's chart as follows):&#xD;
&#xD;
                    -  Within the previous 6 months in subjects with unstable symptoms, or&#xD;
&#xD;
                    -  Within the previous 12 months in subjects with stable symptoms.&#xD;
&#xD;
               2. Clinical evidence (at screening) of heart failure, including abnormal jugular&#xD;
                  venous pressure (JVP) (eg, &gt;8 cm above the clavicle, assessed at 45°angle), rales&#xD;
                  or crackles more than a third above bases, or 2+ lower extremity edema.&#xD;
&#xD;
          -  On optimal background therapy for ADHF (as determined by the investigator); subjects&#xD;
             are required to have received, at a minimum, at least 1 hour of oxygen supplementation&#xD;
             and at least one dose of IV furosemide at a minimum dose of 40 mg with the last bolus&#xD;
             being delivered &gt;2 hours before study drug administration is initiated (or another&#xD;
             diuretic at a comparable dose; eg, 2 mg bumetanide or 20 mg torsemide, with the last&#xD;
             bolus being delivered &gt;4 hours before study drug administration is initiated.&#xD;
&#xD;
          -  If subject received IV opiate, the last dose must have been &gt;3 hours before&#xD;
             administration of study drug.&#xD;
&#xD;
          -  Women of childbearing potential must have a negative pregnancy test prior to being&#xD;
             randomized in the study. Women and men of reproductive potential will agree to utilize&#xD;
             effective contraception during the entire treatment period and for 1 month after&#xD;
             receiving the last dose of ularitide or placebo.&#xD;
&#xD;
          -  Ability to understand the purpose and risks of the study and provide signed and dated&#xD;
             informed consent and authorization to use protected health information (in accordance&#xD;
             with national and local subject privacy regulations).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Any subject will be ineligible for this study if any one of the following criteria is met:&#xD;
&#xD;
          -  Breathing rate &lt;18 breaths per minute (measured during 60 seconds).&#xD;
&#xD;
          -  A systolic blood pressure (SBP) &lt;110 mmHg or &gt;180 mmHg within an hour before&#xD;
             randomization, or SBP &lt;120 mmHg for subjects receiving IV inotropics or vasodilators.&#xD;
             A SBP &lt;90 mmHg in two successive measurements within 30 minutes before randomization.&#xD;
             (Subjects on baseline IV inotropes or vasodilators must be on a stable dose for ³3&#xD;
             hours prior to randomization.)&#xD;
&#xD;
          -  BNP &lt;400 pg/mL or NT?pro-BNP &lt;1200 pg/mL anytime from initial presentation to hospital&#xD;
             to time of randomization.&#xD;
&#xD;
          -  Use of IV contrast material within 48 hours before infusion of study drug.&#xD;
&#xD;
          -  History of central or peripheral neurological ischemic disorder (stroke, etc.).&#xD;
&#xD;
          -  Active myocarditis, obstructive hypertrophic cardiomyopathy, congenital heart disease,&#xD;
             restrictive cardiomyopathy, constrictive pericarditis, severe aortic stenosis,&#xD;
             uncorrected primary valvular disease, or significant obstructive valve disease.&#xD;
&#xD;
          -  Acute decompensated heart failure associated with endocrine (eg, thyroid storm),&#xD;
             metabolic, or drug-related toxicity.&#xD;
&#xD;
          -  Elevation of serum creatinine?kinase myocardial band (CK?MB) or cardiac troponin&#xD;
             (Troponin I) &gt;2 times the upper limit of normal within 6 hours prior to randomization.&#xD;
&#xD;
          -  Active, ongoing myocardial ischemia, hospitalization for acute myocardial infarction,&#xD;
             or administration of thrombolytic therapy in the last 30 days prior to randomization,&#xD;
             or, any ECG abnormalities in the opinion of the investigator, suggestive of active&#xD;
             ischemic changes.&#xD;
&#xD;
          -  Percutaneous coronary intervention, coronary artery bypass graft surgery, other&#xD;
             cardiac surgery, or major noncardiac surgery within 90 days prior to randomization.&#xD;
&#xD;
          -  Any cardiogenic shock (SBP &lt;90 mmHg with signs or symptoms of organ hypoperfusion)&#xD;
             from initial presentation to randomization.&#xD;
&#xD;
          -  Any significant volume depletion or severe electrolyte imbalance.&#xD;
&#xD;
          -  Renal disorder with a creatinine clearance &lt;30 mL/min, as calculated by the&#xD;
             Cockcroft-Gault equation at screening.&#xD;
&#xD;
          -  Use of a phosphodiesterase type 5 (PDE 5) inhibitor such as sildenafil within 72 hours&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Planned coronary revascularization procedure (percutaneous coronary intervention or&#xD;
             coronary artery bypass grafting) during current hospital admission.&#xD;
&#xD;
          -  Use or anticipated need for invasive or noninvasive mechanical circulatory or&#xD;
             ventilatory support.&#xD;
&#xD;
          -  Anemia (hemoglobin &lt;10 mg/dL or a hematocrit &lt;30%).&#xD;
&#xD;
          -  Vasculitis, active infective endocarditis, or suspected infections including pneumonia&#xD;
             or sepsis.&#xD;
&#xD;
          -  Body temperature ≥ 38º C.&#xD;
&#xD;
          -  Significant acute or chronic respiratory disorder (eg, severe chronic obstructive&#xD;
             pulmonary disease) or primary pulmonary hypertension with baseline dyspnea that may&#xD;
             interfere with the ability to interpret dyspnea assessments or hemodynamic&#xD;
             measurements.&#xD;
&#xD;
          -  Terminal illness other than CHF with expected survival &lt;180 days.&#xD;
&#xD;
          -  Previous exposure to ularitide.&#xD;
&#xD;
          -  Nesiritide treatment in the last 30 days prior to randomization.&#xD;
&#xD;
          -  Allergy to natriuretic peptides.&#xD;
&#xD;
          -  Participation in a clinical drug trial or investigational device trial within 30 days&#xD;
             prior to randomization.&#xD;
&#xD;
          -  Current drug abuse or chronic alcoholism (at the Investigator's determination).&#xD;
&#xD;
          -  Women who are pregnant or breast-feeding. Women of childbearing age will have a urine&#xD;
             pregnancy test to determine pregnancy status within 24 hours prior to randomization.&#xD;
&#xD;
          -  Any condition that, in the investigator's opinion, makes the subject unsuitable for&#xD;
             study participation, including a history of repeated admission related to&#xD;
             non-adherence to prescribed medication.&#xD;
&#xD;
          -  For subjects with concomitant invasive hemodynamic monitoring (ie, pulmonary artery&#xD;
             catheter monitoring): Baseline PCWP ≤ 20 mmHg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Cotts, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Feinberg School of Medicine, Northwestern Univ.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gregory Ewald, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daniel Fuleihan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cardiovascular Specialists PC dba New York Heart Ctr</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Barry Greenberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCSD Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Darshak Karia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Albert Einstein Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elie Korban, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kore Cardiovascular Research Institute</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Nowak, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Henry Ford Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nirav Y. Raval, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Atlanta Cardiology Group, PC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSD Medical Center</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Atlanta Cardiology Group, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Feinberg School of Medicine, Northwestern Univ.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardiovascular Specialists PC dba New York Heart Ctr.</name>
      <address>
        <city>Syracuse</city>
        <state>New York</state>
        <zip>13210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albert Einstein Medical Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kore Cardiovascular Research Institute</name>
      <address>
        <city>Lexington</city>
        <state>Tennessee</state>
        <zip>38351</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pdl.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2009</verification_date>
  <study_first_submitted>June 15, 2007</study_first_submitted>
  <study_first_submitted_qc>June 15, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 19, 2007</study_first_posted>
  <last_update_submitted>July 17, 2009</last_update_submitted>
  <last_update_submitted_qc>July 17, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 20, 2009</last_update_posted>
  <keyword>Acute Decompensated Heart Failure</keyword>
  <keyword>ADHF</keyword>
  <keyword>Heart Failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ularitide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

